Breaking News

Novella Clinical Names New Leaders

September 3, 2013

Turunjian, Gault, and Zajd take on oncology, regulatory affairs, and compliance roles

Deborah Turunjian has been named vice president, Oncology Clinical Development at Novella Clinical. Ms. Turunjian will lead expansion of the company’s dedicated oncology division. Previously, Ms. Turunjian served as an executive leader for Novella’s business optimization and vendor management departments in addition to her oversight of western U.S. business operations. She has more than 30 years of experience in business operations overseeing global outsourcing and strategic partnerships in more than 25 countries. She also has 10 years of operational management experience for Phase I, II and III global oncology trials in both sponsor and CRO organizations.
Jamie Gault has been promoted to global head of Regulatory Affairs and will oversee preparation of regulatory packages for agencies globally. Ms. Gault joined the company in 2012 and served in a senior quality assurance role. She has 25 years experience in regulatory roles both at sponsor and CRO organizations. Her regulatory experience spans drugs, biologics, cell and tissue-based products, combination products and medical devices, as well as the management of INDs, IDEs, NDAs, and 510(k)s regulatory submissions.
Also, Kathleen Zajd has been named vice president, Global Quality and Compliance. She previously served on Novella’s senior management team following the acquisition of Prologue Research International in 2010. Prior to co-founding Prologue, Ms. Zajd held leadership roles in clinical operations, regulatory and quality with experience spanning more than 25 years across both service organizations and sponsor companies (pharma and medical device). She has extensive knowledge of GCPs/GLPs, ICH requirements, international directives/laws that govern the conduct of global clinical trials, and is experienced with all aspects of the clinical trial process.
Novella Clinical president and chief executive officer Richard Staub, said, “We are fortunate to work with an extremely high caliber of professionals. I am confident we have the right people in the right positions to propel Novella into our next phase of growth.”

Related Compliance:

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks

  • The Growing Realm of Real-World Data

    Kristin Brooks, Contract Pharma||November 8, 2016
    PPD's Evidera acquisition aims to help clients address the growing demand for evidence from regulators and payers

  • Mastering Immunotherapy Clinical Trials: Dosing and Response

    Mastering Immunotherapy Clinical Trials: Dosing and Response

    Kristin Brooks, Contract Pharma||August 1, 2016
    Andrew Zupnick of Novella Clinical provides insights into dosing and measuring response in immunotherapy clinical trials